OmniaBio provides specialized, focused, cGMP-compliant contract development and manufacturing organization (CDMO) services for cell and gene therapy (CGT) developers. As a CCRM subsidiary, OmniaBio is building on an established foundation and reputation in manufacturing for CGTs, expanding on a team and legacy that has been built over a decade.
Find out more about our existing and upcoming manufacturing infrastructure.
COLLABORATIVE, CLIENT-FOCUSED PROJECT MANAGEMENT
OmniaBio is an extension of your team. We work with you to produce a comprehensive manufacturing plan that identifies opportunities to build in efficiencies, saving you time and money. Our team is recognized for its transparent client-centric approach to problem solving.
iPSC, LVV and IMMUNOTHERAPY PLATFORM LEADERSHIP
With teams experienced in generating and characterizing over 200 induced pluripotent stem cell (iPSC) lines, OmniaBio can deliver high-quality iPSCs that meet the unique requirements of each client, with GMP-compliant reprogramming platforms to produce therapeutic-grade iPSC lines. OmniaBio is built upon leadership in iPSCs, LVV and Immunotherapy, and these are just three of 11 areas of extensive expertise that OmniaBio builds upon.
Find out more about our platform leadership.